Suzanne van Voorthuizen

“There was a change in the dosing regimen between phase two and three, and the phase three is also a head-to-head. Could you elaborate on how you navigate the potential risks that these two changes introduce, what gives you comfort that the study can confirm EMPA's non-inferiority.”